Shoulder Innovations stock initiated with Overweight rating at Morgan Stanley

Published 25/08/2025, 13:46
Shoulder Innovations stock initiated with Overweight rating at Morgan Stanley

Investing.com - Morgan Stanley has initiated coverage on Shoulder Innovations (NYSE:SI) with an Overweight rating and a price target of $18.00, representing significant upside potential from the current trading price of $12.71. The small-cap medical device company, with a market capitalization of $281 million, has demonstrated strong gross margins of 77%.

The investment bank cites the company’s differentiated shoulder implant technology as a key factor in its ability to capture market share in one of the fastest growing orthopedic segments.

Morgan Stanley acknowledges that Shoulder Innovations’ small-cap profile adds execution risk to the investment thesis.

Despite this risk factor, the firm believes that ambulatory surgery center (ASC) uptake, clear surgeon adoption trends, and underlying margin strength position the company favorably.

These factors collectively support Morgan Stanley’s view that Shoulder Innovations has potential for meaningful upside, leading to the Overweight rating and $18.00 price target.

In other recent news, several prominent financial firms have initiated coverage on Shoulder Innovations with positive ratings. BTIG has given the company a Buy rating with a price target of $23.00, focusing on the high-growth potential of the shoulder arthroplasty market, particularly highlighting the InSet Glenoid product. Piper Sandler also initiated coverage with an Overweight rating and a price target of $18.00, praising the company’s unique shoulder replacement implants that reportedly deliver better clinical outcomes. Jefferies joined in with a Buy rating and a $19.00 price target, noting the company’s potential market share gains and estimating future sales. Goldman Sachs similarly provided a Buy rating, setting a $20.00 price target, and emphasized Shoulder Innovations’ revenue growth and market potential. These developments reflect a positive outlook from multiple analysts regarding the company’s future prospects in the medical technology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.